New Drugs: 2017 - Till August
➖➖➖➖➖➖➖➖➖➖➖➖
New Drugs: 2017 - Till August
➖➖➖➖➖➖➖➖➖➖➖➖
1. Avelumab: Anti PD1 (Programmed Death ligand 1 Ab approved for metastatic Merkel cell carcinoma.
2. Dupilumab: Anti IL 4 receptor alpha antibody approved for treatment of atopic dermatitis.
3. Brodalumab: Anti IL 17 A receptor Ab approved for treatment of plaque psoriasis.
4. Plecanatide: Guanylate cyclase c stimulator approved for treatment of chronic idiopathic constipation. It increases cyc GMP, which stimulates CTFR ( Cystic Fibrosis Transmembrane Regulator), which increases Cl ion secretion in to gut.
5. Naldenedine: Opioid antagonist approved for treatment of opioid induced constipation.
6. Telotristat: Tryptophan hydroxylase inibitor approved for treatment of carcinoid syndrome. It inhibits serotonin synthesis.
7. Midostaurin: Multikinase inhibitor approved for treatment of
• AML: Along with TOC (Cytarabine + Daunorobicin) in FLT3 mutation positive cases.
• Aggressive systemic mastocytosis
• Systemic mastocytosis with hematological neoplasm
• Mast cell leukemia
8. Ocrelizumab: Anti CD20 Ab approved for treatment of RRMS and PPMS.
9. Deflazacort: Corticosteroid approved for treatment of Duchenne muscular dystrophy.
10. Abolaparatide: PTH anaog approved for treatment of resistant postmenopausal osteoporosis at high risk of fracture.
11. Deutetrabenazine: VMAT 2 inhibitor approved for treatment of Hutington's chorea.
12. Valbenazine: VMAT 2 inhibitor approved for treatment of tardive dyskinesia.
13. Safinamide: MAO B inhibitor approved for treatment of on off phenomena seen with levodopa.
14. Rivociclib: CDK (Cyclin Dependent Kinase) 4 and 6 inhibitor approved for treatment of ER +ve post menopausal breast cancer along with aromatase inhibitors.
15. Niraparib: Poly ADP-Ribose Polymerase (PARP) inhibitor approved for treatment of ovarian, fallipian tube and primary peritoneal cancer resistant to cisplatin.
16. Brigatinib: Multikinase inhibitor approved for treatment of advanced ALK-positive metastatic non-small cell lung cancer.
17. Betrixaban - Oral factor Xa inhibitor approved for pophylaxis of venous thromboembolism.
18. Delafloxacin - A new fluoroquinolone approved for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by both gram positive and negative organisms.
19. Guselkumab - Anti IL 23 MAb approved for treatment of plaque psoriasis.
20. Dapagliflozin + Saxagliptin: FDC approved for treatment of type II DM.
21. Inotuzumab ozogamycin: Anti CD 22 MAb approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
22. Enasidenib: It is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme that works by blocking several enzymes that promote cell growth. It is approved for treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation.
23. Glecaprevir (Hep C protease inhibitor) and Pibrentasvir (Hep C NS5A inhibitor): FDC approved for treatment of hepatitis C.
24. Meropenam + Vaborbactam - Approved for treatment of complicated UTI.
25. Lesinurad (Uricosuric) + Allopurinol: FDC approved for gout in case of allopurinol ineffectiveness.
26. Sarilumab: Anti IL6 MAb approved for treatment of rheumatoid arthritis.
27. Edaravone: It is a free radical scavenger approved for treatment of ALS.
28. Amantidine: Approved for treatment of dyskinesia in PD.
29. Neratinib: Inhibitor of EGFR, HER-2 and Her-4 tyrosine kinase approved for treatment of trastuzumab resistant breast cancer.
#new_drugs
New Drugs: 2017 - Till August
➖➖➖➖➖➖➖➖➖➖➖➖
1. Avelumab: Anti PD1 (Programmed Death ligand 1 Ab approved for metastatic Merkel cell carcinoma.
2. Dupilumab: Anti IL 4 receptor alpha antibody approved for treatment of atopic dermatitis.
3. Brodalumab: Anti IL 17 A receptor Ab approved for treatment of plaque psoriasis.
4. Plecanatide: Guanylate cyclase c stimulator approved for treatment of chronic idiopathic constipation. It increases cyc GMP, which stimulates CTFR ( Cystic Fibrosis Transmembrane Regulator), which increases Cl ion secretion in to gut.
5. Naldenedine: Opioid antagonist approved for treatment of opioid induced constipation.
6. Telotristat: Tryptophan hydroxylase inibitor approved for treatment of carcinoid syndrome. It inhibits serotonin synthesis.
7. Midostaurin: Multikinase inhibitor approved for treatment of
• AML: Along with TOC (Cytarabine + Daunorobicin) in FLT3 mutation positive cases.
• Aggressive systemic mastocytosis
• Systemic mastocytosis with hematological neoplasm
• Mast cell leukemia
8. Ocrelizumab: Anti CD20 Ab approved for treatment of RRMS and PPMS.
9. Deflazacort: Corticosteroid approved for treatment of Duchenne muscular dystrophy.
10. Abolaparatide: PTH anaog approved for treatment of resistant postmenopausal osteoporosis at high risk of fracture.
11. Deutetrabenazine: VMAT 2 inhibitor approved for treatment of Hutington's chorea.
12. Valbenazine: VMAT 2 inhibitor approved for treatment of tardive dyskinesia.
13. Safinamide: MAO B inhibitor approved for treatment of on off phenomena seen with levodopa.
14. Rivociclib: CDK (Cyclin Dependent Kinase) 4 and 6 inhibitor approved for treatment of ER +ve post menopausal breast cancer along with aromatase inhibitors.
15. Niraparib: Poly ADP-Ribose Polymerase (PARP) inhibitor approved for treatment of ovarian, fallipian tube and primary peritoneal cancer resistant to cisplatin.
16. Brigatinib: Multikinase inhibitor approved for treatment of advanced ALK-positive metastatic non-small cell lung cancer.
17. Betrixaban - Oral factor Xa inhibitor approved for pophylaxis of venous thromboembolism.
18. Delafloxacin - A new fluoroquinolone approved for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by both gram positive and negative organisms.
19. Guselkumab - Anti IL 23 MAb approved for treatment of plaque psoriasis.
20. Dapagliflozin + Saxagliptin: FDC approved for treatment of type II DM.
21. Inotuzumab ozogamycin: Anti CD 22 MAb approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
22. Enasidenib: It is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme that works by blocking several enzymes that promote cell growth. It is approved for treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation.
23. Glecaprevir (Hep C protease inhibitor) and Pibrentasvir (Hep C NS5A inhibitor): FDC approved for treatment of hepatitis C.
24. Meropenam + Vaborbactam - Approved for treatment of complicated UTI.
25. Lesinurad (Uricosuric) + Allopurinol: FDC approved for gout in case of allopurinol ineffectiveness.
26. Sarilumab: Anti IL6 MAb approved for treatment of rheumatoid arthritis.
27. Edaravone: It is a free radical scavenger approved for treatment of ALS.
28. Amantidine: Approved for treatment of dyskinesia in PD.
29. Neratinib: Inhibitor of EGFR, HER-2 and Her-4 tyrosine kinase approved for treatment of trastuzumab resistant breast cancer.
#new_drugs
Comments
Post a Comment